- The disease
- Ventricular tachycardia (VT) is a fast, abnormal heart rhythm that starts in the ventricles (the heart's lower chambers). It can cause fainting, cardiac arrest, and death, particularly in patients who have underlying structural heart disease such as scarring from a prior heart attack. Catheter ablation is a procedure in which a long, thin tube is guided into the heart to destroy the small areas of tissue that are triggering the abnormal rhythm. Identifying and targeting those areas precisely is a known challenge with conventional approaches.
- What the asset is trying to do
- The Vision-MR Ablation Catheter is a medical device designed to be used inside a magnetic resonance imaging (MRI) scanner during a live ablation procedure. Conventional ablation catheters cannot be used inside an MRI scanner because standard metal instruments are incompatible with the strong magnetic field. Imricor's device is built from MRI-compatible materials, allowing the operator to view real-time, high-resolution images of the heart's anatomy and scar tissue at the same time as delivering radiofrequency energy to ablate the target tissue.
- What the trial is measuring, and why it matters
- The lead trial (NCT05543798) is evaluating the Vision-MR Ablation Catheter 2.0 in patients with ventricular tachycardia within an interventional cardiac MRI (iCMR) environment (per ClinicalTrials.gov NCT05543798). The trial's specific primary endpoint details are . Endpoints in device ablation studies typically cover procedural success, safety events, and freedom from recurrence, as these directly reflect whether the device performs as intended and whether patients benefit from the procedure.
- Efficacy benchmarks in this setting
- For VT ablation using conventional (non-MRI-guided) catheter systems, published data from landmark studies such as the VANISH trial (Sapp et al, New England Journal of Medicine, 2016) reported that catheter ablation reduced a composite of death, VT storm, or appropriate implantable defibrillator shock compared with escalated antiarrhythmic drug therapy in patients with prior myocardial infarction. Acute procedural success rates and longer-term VT recurrence figures vary substantially across published series depending on patient population and centre experience. Any figures reported from early enrolment in NCT05543798 involve small numbers of patients and are not statistically comparable to results from larger randomised or registry studies of established systems.
- Commercial context